AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2659874
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg finoptin
Trial: 2659874
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fosfobion
Trial: 28482839
Drug: Alkanna tinctoria
RxNorm normalized name: ALKANNA TINCTORIA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkanna tinctoria extract ointment (20%)
Trial: 21770995
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement (MDA) using carbon curets and antiseptic therapy with chlorhexidine digluconate
Trial: 19309347
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolevulinate (MAL) photodynamic therapy (PDT)
Trial: 1561524
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg every morning for 10 days)
Trial: 4015380
Drug: Combined radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiation and fluorouracil as adjuvant therapy
Trial: 29121431
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate (CP) in aqueous solution (AS)
Trial: 29121431
Drug: 0.05% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% triamcinolone acetonide (TA) in aqueous solution (AS)
Trial: 29121431
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment for >6 months
Trial: 27615399
Drug: Annual trans-vaginal
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual trans-vaginal ultrasound (TVU) for 4 years and CA-125 testing for 6 years with a cutoff at 35 U/mL
Trial: 19083452
Drug: 1.5-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-g dose of strong-gelling alginate
Trial: 12941422
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies used to deplete lymphocytes or block T-cell function
Trial: 12941422
Drug: Conventional immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppressive agents
Trial: 7595729
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PC) with cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF)
Trial: 7595729
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PC)
Trial: 2151889
Drug: Enoximone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.5 mg/kg) + epinephrine (0.1 micrograms/kg/min)
Trial: 28370357
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow-derived MSCs infused weekly for 4 weeks (1.0 to 10 × 10^5 cells/kg)
Trial: 26215351
Drug: Cuddle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuddle therapy
Trial: 23692975
Drug: Listerine® oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine® oral rinse twice daily
Trial: 23692975
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate oral rinse 2/24
Trial: 21718471
Drug: 6 month
RxNorm normalized name: LEUPROLIDE (CAMCEVI) 42MG (6 MONTH) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 month intensive inpatient treatment program during weekdays, followed by six monthly return visits of 2 days (Group A)
Trial: 21718471
Drug: 2 month
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 month intensive inpatient treatment program during weekdays, followed by biweekly return visits of 2 days during the next four months, followed by six monthly return visits of 2 days (Group B)
Trial: 2643237
Drug: Valaxon tablets
RxNorm normalized name: MALAOXON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaxon tablets
Trial: 2643237
Drug: Valium tablets
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valium tablets
Trial: 27347034
Drug: Piperazine ferulate
RxNorm normalized name: ferulate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules
Trial: 27347034
Drug: Conservative or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative or hormone therapy
Trial: 22413874
Drug: DRV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r monotherapy (strict ITT analysis)
Trial: 20801496
Drug: 110 mg
RxNorm normalized name: lactase 110 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 mg dabigatran
Trial: 20801496
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg dabigatran
Trial: 9647138
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (30,000 KIU/kg)
Trial: 9647138
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (15,000 KIU/kg)
Trial: 9647138
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin with additional bolus
Trial: 8702066
Drug: Early growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early growth modification treatment for Class II malocclusion (duration: 15 months)
Trial: 343994
Drug: scopolamine-N-(cyclopropyl methyl)
RxNorm normalized name: (-)-scopolamine methyl bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine-N-(cyclopropyl methyl) bromide (DA 3177) at doses of 2.5 mg and 5 mg i.v.
Trial: 343994
Drug: hyoscine-N-butyl bromide
RxNorm normalized name: n-butyl acrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyoscine-N-butyl bromide at doses of 10 mg and 20 mg i.v.
Trial: 28508114
Drug: L-menthol mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-menthol mouthwash
Trial: 31654487
Drug: Evobrutinib (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib (single dose: 25, 50, 100, 200, 350, and 500 mg)
Trial: 31654487
Drug: Evobrutinib (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib (multiple dosing: 25, 75, and 200 mg/day for 14 days)
Trial: 31654487
Drug: Evobrutinib (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib (≥ 200 mg single dose)
Trial: 31654487
Drug: Evobrutinib (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib (≥ 100 mg)
Trial: 31654487
Drug: Evobrutinib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evobrutinib (25 mg multiple dosing)
Trial: 29105625
Drug: Jin'gangteng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin'gangteng capsule combined with Kangfuxiaoyan suppository
Trial: 29105625
Drug: Kangfuxiaoyan suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangfuxiaoyan suppository
Trial: 23413101
Drug: Omalizumab 150
RxNorm normalized name: omalizumab 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 150 to 375 mg subcutaneously every 2 or 4 weeks from week 0 to 48
Trial: 19231138
Drug: 5mg intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg intranasal diazepam (DZP)
Trial: 19231138
Drug: 10mg intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg intranasal diazepam (DZP)
Trial: 19231138
Drug: 5mg intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg intravenous diazepam (DZP injectable, 5mg/mL)
Trial: 17268414
Drug: Herring diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herring diet (150 g baked herring fillets/day, 5 days/week)
Trial: 9382049
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg a day for 1 month and amoxycillin 1 g three times daily for 14 days
Trial: 8369641
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg d,l‐fenfluramine (FEN)
Trial: 6145027
Drug: UK-38,485 (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-38,485 (specific thromboxane synthetase inhibitor)
Trial: 31609920
Drug: Conditioned group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioned group (oxytocin nasal spray with a distinctive smell)
Trial: 31609920
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo spray)
Trial: 31609920
Drug: Drug control
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug control group (oxytocin spray)
Trial: 30757911
Drug: Linfadren® plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linfadren® plus conventional treatment
Trial: 25331203
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with bupivacaine at a dose of 2.5 mg · kg(‐1)
Trial: 25331203
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with bupivacaine at a dose of 1.25 mg · kg(‐1)
Trial: 18268396
Drug: Interferon-alpha2a (IFN-alpha2a)
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2a (IFN-alpha2a) administered for 6 days starting 1 week before nephrectomy.
Trial: 18268396
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with IFN-alpha2a).
Trial: 17133610
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone and 6 infusions (monthly) of intravenous cyclophosphamide (CYC) followed by oral azathioprine (AZA)
Trial: 8857479
Drug: simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 10 mg bid
Trial: 1629507
Drug: Budesonide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (600 micrograms, twice daily)
Trial: 1629507
Drug: Terbutaline (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (375 micrograms, twice daily)
Trial: 6860201
Drug: 0.125% betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% betaxolol ophthalmic solution
Trial: 16687979
Drug: Placebo (drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (drug vehicle)
Trial: 31919749
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil plus Chinese medicine (Tiaogan Jianpi Hexue and Tiaogan Jiedu Huashi)
Trial: 30691922
Drug: Intracameral 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral 0.5% moxifloxacin (0.03 mL, 150 μg)
Trial: 30691922
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IC medication)
Trial: 28513523
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy for 2 weeks
Trial: 28513523
Drug: Bismuth containing
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth containing quadruple therapy for 2 weeks
Trial: 28513523
Drug: 5 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 + 5 clarithromycin‐based sequential therapy
Trial: 28513523
Drug: 7 +
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 + 7 clarithromycin‐based sequential therapy
Trial: 26037777
Drug: Tocilizumab discontinuation
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab discontinuation
Trial: 21644315
Drug: Moxibustion pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion pretreatment (mild moxibustion applied at Guanyuan (CV 4), Zusanli (ST 36) or Guanyuan (CV 4), Sanyinjiao (SP 6) alternatively once daily for 4 weeks)
Trial: 20108857
Drug: Intramuscular pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular pressure (IMP) during isometric fatiguing extension at 60% of maximum voluntary contraction
Trial: 15288698
Drug: L‐NMMA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA infusion
Trial: 8290916
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin 70 mg/m2 and doxorubicin 30 mg/m2, 2 cycles with 3-week interval)
Trial: 3565525
Drug: Workbook-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Workbook-based occupational therapy program
Trial: 26452230
Drug: Traditional occupational
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional occupational therapy
Trial: 26468947
Drug: Lapatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib at 750 mg
Trial: 26468947
Drug: Lapatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib at 1,000 mg
Trial: 26468947
Drug: Lapatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib at 1,250 mg
Trial: 21227012
Drug: Controlled ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian hyperstimulation (COH) using triptorelin 0.1 mg/day SC and recombinant FSH 150 - 300 IU/day
Trial: 21227012
Drug: Modified natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified natural cycle (MNC) treatment using HMG 150 IU/day IM if serum oestradiol was ≤ 50 pg/ml
Trial: 10382235
Drug: BIPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIPAP therapy (n = 47)
Trial: 10382235
Drug: Unassisted oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unassisted oxygen therapy (n = 46)
Trial: 2871492
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (1.5 million IU, one-hour infusion)
Trial: 31549624
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet containing amlodipine and rosuvastatin
Trial: 31549624
Drug: Individual tablets
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual tablets of amlodipine and rosuvastatin (reference drugs)
Trial: 30032806
Drug: Perampanel (PER)
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel (PER) adjunctive therapy
Trial: 24641638
Drug: Prophylactic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic epidural blood patch
Trial: 24641638
Drug: Therapeutic epidural
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic epidural blood patch
Trial: 8567109
Drug: Screening tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening tests including PSA serum determination, rectal examination, and transrectal ultrasonography.
Trial: 29878867
Drug: CT-cetux-RT (cetuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-cetux-RT (cetuximab plus radiotherapy with concurrent carboplatin and fluorouracil)
Trial: 23094708
Drug: MN-221 (bedoradrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN-221 (bedoradrine sulfate) via intravenous infusion
Trial: 20823434
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to nevirapine-based therapy (n = 96)
Trial: 16273650
Drug: TPN supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN supplemented with 0.417 g L-alanyl-L-glutamine (Ala-Gln)/kg per day
Trial: 16273650
Drug: Conventional TPN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional TPN solution receiving 1.5 g amino acids/kg per day
Trial: 11812714
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's at 20 mL/kg starting at the time of spinal block
Trial: 11812714
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's at 20 mL/kg starting 20 min before spinal block
Trial: 11812714
Drug: Placebo (lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactated Ringer's solution at 1-2 mL/min)
Trial: 7741778
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet formulation of tiracizine
Trial: 2203300
Drug: FCE 22891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 22891 (oral prodrug of FCE 22101)
Trial: 7048188
Drug: Benzocaine (7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine (7.5% in propylene glycol gel)
Trial: 16904812
Drug: D2-dopamine antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2-dopamine antagonist sulpiride during n-back working memory tasks
Trial: 16368447
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (N-acetylcysteine 600 mg/d, vitamin E 300 mg/d, vitamin C 250 mg/d)
Trial: 2692652
Drug: Epirubicin 20
RxNorm normalized name: epiRUBicin 200 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 20 mg weekly bolus injection
Trial: 2692652
Drug: Epirubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 40 mg weekly bolus injection
Trial: 2692652
Drug: Epirubicin 24-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 24-h infusion
Trial: 31866533
Drug: Methylaminolevulinate (MAL)‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylaminolevulinate (MAL)‐based PDT in three sessions with a light dose of 90 J/cm2 delivered in a single fraction in each session (Group I)
Trial: 31866533
Drug: Methylaminolevulinate (MAL)‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylaminolevulinate (MAL)‐based PDT in three sessions with the light dose delivered in three fractions (Group II)
Trial: 19081156
Drug: 0.01% rh-PDGF-BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% rh-PDGF-BB gel
Trial: 9203721
Drug: IPV followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV followed by OPV (sequential schedules)
Trial: 9203721
Drug: Two IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two IPV doses followed by two OPV doses (optimal schedule)
Trial: 9203721
Drug: Prior OPV
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior OPV doses (two or more)
Trial: 7968593
Drug: Monophasic combination
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene for 12 consecutive cycles
Trial: 3377156
Drug: oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral metoclopramide
Trial: 30033117
Drug: Selective Internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Internal Radiation Therapy (SIRT) plus mFOLFOX6 chemotherapy
Trial: 27536069
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg daily for 6 months
Trial: 27536069
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (PCOS without treatment)
Trial: 25711607
Drug: Delayed-dose oral
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-dose oral rotavirus vaccine
Trial: 25711607
Drug: Injectable polio
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable polio vaccine replacing one dose of oral polio vaccine
Trial: 23865123
Drug: Ginger in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger in capsule form for 3 days
Trial: 18258768
Drug: Group-based high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based high-intensity interval training program (aerobic, resistance, flexibility, and balance activities), twice per week for 16 weeks.
Trial: 9228372
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 70 mg/kg, n=14
Trial: 9228372
Drug: L-2-oxothiazolidine-4-carboxylate (Procysteine;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-2-oxothiazolidine-4-carboxylate (Procysteine; OTZ) 63 mg/kg, n=17